Garuda Wins Big: Revolutionizing Stem Cell Therapy
Garuda Therapeutics has been honored with the prestigious title of “Overall Cell Biology Company of the Year” by BioTech Breakthrough, an independent organization that recognizes top performers in the life sciences and biotechnology sectors. This accolade was awarded to Garuda for their innovative approach to creating off-the-shelf hematopoietic stem cell (HSC) therapies. These therapies are […]
Avid Bioservices Partners with California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs
Avid Bioservices, a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it has partnered with the California Institute for Regenerative Medicine (CIRM), California’s stem cell agency, to provide contract development and manufacturing (CDMO) services for cell and gene therapy (CGT) programs funded by CIRM. Through this partnership, Avid will make its CGMP […]
Tract Bio Unveils Key to CF Lung Inflammation
Tract Bio, a biotechnology company focused on developing therapies for cancer and inflammatory diseases, has recently announced a significant publication in the American Journal of Respiratory and Critical Care Medicine. The publication details their research on stem cell variants that contribute to chronic lung inflammation in cystic fibrosis patients treated with CFTR modulators. Key Highlights […]
Revolutionary ExoPTEN Therapy: FDA’s New Hope for Spinal Injuries
NurExone Biologic Inc., a leading biotechnology company, has recently achieved a significant milestone in the development of treatments for acute spinal cord injuries. The U.S. Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) to the company’s innovative ExoPTEN therapy. This designation is crucial for conditions like acute spinal cord injury, where effective treatments […]
Revolutionizing Cystic Fibrosis: DNA Tech Breakthrough
Moligo Technologies has entered into a collaboration with Nationwide Children’s Hospital to provide long, single-stranded DNA (ssDNA) for research into gene therapies for cystic fibrosis (CF) and other airway diseases. Moligo’s innovative enzymatic DNA production technology produces ultrapure, long ssDNA at an industrial scale. This technology is especially promising as it can introduce chemical modifications, […]
Neurona Therapeutics’ Progress in Phase I/II Clinical Trial of NRTX-1001 Cell Therapy for Drug-resistant Focal Ep
Neurona Therapeutics, a clinical-stage biotherapeutics company, recently announced the completion of enrollment for the first cohort in its ongoing Phase I/II clinical trial of NRTX-1001. This investigational allogeneic cell therapy is being developed to treat drug-resistant mesial temporal lobe epilepsy (MTLE). The first cohort consisted of five subjects who received a one-time dose of NRTX-1001, […]
Coeptis Therapeutics Expands Collaboration with University of Pittsburgh on CAR NK Cell Therapy
Biotech startup Coeptis Therapeutics announced an expanded partnership with the University of Pittsburgh today, licensing additional CAR NK cell therapy technology developed at Pitt. This new agreement builds on their existing collaboration around a CD19-targeting CAR NK cell therapy for blood cancers. The new technology, known as SNAP CAR NK cells, allows for more precise […]
Be The Match BioTherapies and Cryoport Join Forces to Propel Cell and Gene Therapy Advancements
In a groundbreaking move, Be The Match BioTherapies®, a pioneering organization that offers solutions for companies venturing into the development and commercialization of cell and gene therapies, has announced a strategic partnership with Cryoport, a global leader in providing innovative products and services to the rapidly evolving cell & gene therapy sector. A Partnership for […]
Exciting Advancements in Epilepsy Treatment: Neurona Therapeutics’ Breakthrough Research
Neurona Therapeutics, a pioneering biotherapeutics company, has recently unveiled groundbreaking research in the realm of regenerative cell therapy for neurological disorders. Their latest publication highlights the potential of a unique cell therapy approach to treat focal epilepsy, a condition that has long challenged the medical community due to its resistance to conventional drugs. Key Findings […]
NeuroSense’s PrimeC Shows Remarkable Impact on ALS Survival Using Innovative iPSC Model
In a groundbreaking study, NeuroSense’s PrimeC has demonstrated a significant effect on the survival rate of induced motor neurons in an innovative in vitro model. This research was conducted in collaboration with the University of Southern California’s Ichida Stem Cell Lab. The study utilized induced pluripotent stem cells (iPSCs) derived from individuals diagnosed with ALS. […]